Nanobiotix S.A. (NBTX)
NASDAQ: NBTX · IEX Real-Time Price · USD
5.69
+0.19 (3.45%)
Apr 19, 2024, 12:48 PM EDT - Market open
Company Description
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.
Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
Nanobiotix S.A.
| Country | France |
| Founded | 2003 |
| IPO Date | Dec 11, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 102 |
| CEO | Laurent Levy Ph.D. |
Contact Details
Address: 60 Rue De Wattignies Paris, I0 75012 France | |
| Phone | 33140260470 |
| Website | nanobiotix.com |
Stock Details
| Ticker Symbol | NBTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $13.50 |
| CIK Code | 0001760854 |
| CUSIP Number | 63009J107 |
| ISIN Number | US63009J1079 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Laurent Levy Ph.D. | Co-Founder, President of the Executive Board and Chief Executive Officer |
| Bart Van Rhijn | Chief Financial Officer and Member of Executive Board |
| Anne-Juliette Hermant M.A. | Chief People Officer and Member of Executive Board |
| Earl J. Bergey Ph.d. | Co-Founder |
| Alain Dostie | Chief Operating Officer |
| Craig West CFA | Senior Vice President of Investor Relations |
| Brandon Owens | Vice President of Strategic Marketing and Corporate Communication |
| Patrick Tricoli M.B.A., Pharm.D. | Global Head of Business Development |
| Margaret Galluzzi | Vice President and Global Head of Clinical Operations |
| Ventzislav Vassilev M.D. | Vice President and Global Head of Safety Vigilance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2024 | 6-K | Report of foreign issuer |
| Apr 10, 2024 | 6-K | Report of foreign issuer |
| Apr 2, 2024 | 6-K | Report of foreign issuer |
| Mar 6, 2024 | 6-K | Report of foreign issuer |
| Feb 13, 2024 | 6-K | Report of foreign issuer |
| Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 2, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 31, 2024 | 6-K | Report of foreign issuer |
| Jan 29, 2024 | 6-K | Report of foreign issuer |